Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 6 Time to progression

	All procedures (n = 169)	TARE_alone (n = 63)	TARE_sorafenib (n = 81)	TARE_no_sorafenib (n = 25)
Treated area
Censored patients	87	39	37	11
TTP, mo	7.8 (6.4-9.3)	12.3 (10.4-14.1)	7.5 (6.2-8.8)	3.6 (0.8-6.4)
Untreated area
Censored patients	119	47	59	13
TTP, mo	12.8 (4.3-21.3)	22.9 (10.2-35.7)	11.9 (8.0-15.8)	3.6 (2.1-5.1)
Overall
Censored patients	58	27	24	7
TTP, mo	4.9 (3.9-5.9)	8.6 (3.4-13.8)	5.1 (4.0-6.2)	2.7 (2.2-3.1)

TTP values represent median (95%CI) in months. TTP: Time to progression; TARE: Transarterial radioembolization.